Compare Quest Diagnostics Inc (DGX) vs Workday Inc (WDAY) Price & Performance

Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.

The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.

Workday (WDAY) trades at $185.67, up 0.77% with neutral technical signals and strong fundamental momentum. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth remains robust, projected to reach $10.2B in 2026, while profitability metrics show improvement. Recent strategic moves include expansion into the UAE market and AI product launches, though layoffs and a fraud investigation present headwinds. Analyst consensus leans bullish with a $202.92 price target, suggesting 9% upside potential from current levels.

WDAY presents a compelling growth story with AI-driven revenue acceleration and expanding profit margins, but faces execution risks amid restructuring and competitive pressures. The stock's premium valuation (P/E 38.25) requires sustained high growth to justify current levels. Institutional sentiment remains positive despite near-term volatility, with the key catalyst being Q3 earnings delivery against expectations of $2.74 EPS.